Treatment with once-weekly cagrilintide (0.16, 0.30, 0.60, 1.2, 2.4, and 4.5 mg) in combination with semaglutide 2.4 mg for 20 weeks was not associated with an increase in adverse events compared with placebo in combination with semaglutide 2.4 mg, with no unexpected safety or tolerability findings
doi:10.1111/j.1471-4159.2006.03693.x
This is the fundamental principle that governs dosing schedules
Here are just a few examples of how our providers (and you) can implement Guttides to enhance patient outcomes: Gut health improvement Gastric reflux disease Antiulcer properties Joint pain/inflammation Soft tissue injury Autoimmune support Improves nerve generation Counteracts QT prolongation Acne Hair growth and support
Authors' contributions OB developed the structural design of the review, coordinated the work and did together with SJ the major part of drafting of the manuscript
No side effects were noted from the treatment